中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

40 records (took 0.01 seconds)

    Thermal conversion of CBDA and other carboxylic cannabinoids
    2.
    发明授权
    Thermal conversion of CBDA and other carboxylic cannabinoids 有权

    公开(公告)号：US12071419B2

    公开(公告)日：2024-08-27

    申请号：US17727788

    申请日：2022-04-24

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: C07D311/80 ,  B01J3/04 ,  C07C37/50 ,  C07C37/74 ,  C07C39/19

    CPC classification number: C07D311/80 ,  B01J3/04 ,  C07C37/50 ,  C07C37/74 ,  C07C39/19

    Abstract: This invention is for improving the manufacturing pharmaceutical grade CBD and other cannabinoids following current Good Manufacturing Practices (cGMP) of the US FDA for use in clinical trials for CNS and other indications by the NIH and other researchers. The major cannabinoids in marijuana (Cannabis) and hemp originate from Cannabigerolic Acid (CBGA) present in the biomass of the plant. Plant enzymes that are specific to different strains of biomass converts CBGA to different carboxylic acids of cannabinoids including Cannabidiolic Acid (CBDA) and Δ9-Tetrahydrocannabinolic Acid (Δ9-THCA). These are relatively stable in the growing and fresh-cut plants. These are converted by thermal decarboxylation to Cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC), carbon dioxide and water. Cannabinoids can be manufactured by first heating the Cannabis biomass to convert carboxylic acids prior to extraction and purification. Alternatively, and preferably because of manufacturing cost and product stability, the carboxylic acids can be first extracted and purified. They can be utilized in the carboxylic acid form or stored in a stable manner until converted to cannabinoids for use in medicine. This invention provides an efficient method for their conversion utilizing a high-pressure reactor under inert conditions.

    Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product
    4.
    发明授权
    Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product 有权
    联合药物和共包胶合药物产品的共包封方法

    公开(公告)号：US08637074B2

    公开(公告)日：2014-01-28

    申请号：US12384007

    申请日：2009-03-31

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: A61K9/127 ,  A61P35/00

    CPC classification number: A61K9/127 ,  A61K9/1271 ,  A61K9/1277 ,  A61K31/4745 ,  A61K45/06 ,  A61K2300/00

    Abstract: This invention is for an improved process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid liposomes. Non-toxic supercritical or near-critical fluids with/without polar cosolvents are utilized to solubilize phospholipid materials and hydrophobic drugs, and form uniform liposomes to encapsulate hydrophobic drugs and hydrophilic drugs.

    Abstract translation: 本发明是为了在磷脂脂质体中共同包封疏水药物和亲水药物的改进方法。 使用具有/不具有极性助溶剂的无毒超临界或近临界流体来溶解磷脂材料和疏水性药物，并形成均匀的脂质体以包封疏水性药物和亲水性药物。

    Methods for making Hypericum fractions and St. John's Wort products
    5.
    发明授权
    Methods for making Hypericum fractions and St. John's Wort products 失效
    制造金丝桃馏分和圣约翰草产品的方法

    公开(公告)号：US06291241B1

    公开(公告)日：2001-09-18

    申请号：US09280366

    申请日：1999-03-29

    Applicant: Trevor Percival Castor ,  Theodore Abraham Tyler ,  Richard Joseph Student

    Inventor： Trevor Percival Castor ,  Theodore Abraham Tyler ,  Richard Joseph Student

    IPC: B01D5940

    CPC classification number: A61K36/38 ,  C07C45/78 ,  Y02P20/544 ,  C07C49/743

    Abstract: St. John's Wort products which have enhanced bioactivity in a serotonin re-uptake assay and enhanced stability are identified and manufactured from Hypericum perforatum biomass with supercritical and near critical fluids with and without polar cosolvents. These fluids are used to fractionate the biomass materials in several sequential steps. In each step, the biomass is subjected to a multiplicity of supercritical or near critical fluid extraction steps, with different solvation conditions used for each fraction. Thus, fractionation of the biomass is effected and the St. John's Wort products are manufactured. In addition to excellent overall yield, the bioactivity and stability of the St. John's Wort products manufactured from Hypericum perforatum biomass with supercritical and near critical fluids with and without polar cosolvents are significantly higher than that obtained by conventional organic phase extraction.

    Abstract translation: 在具有和不具有极性助溶剂的超临界和近临界流体的情况下，鉴定并制造了具有提高5-羟色胺再吸收测定和增强稳定性的生物活性的圣约翰草产品。 这些流体用于在几个连续步骤中分解生物质材料。 在每个步骤中，生物质经受多个超临界或近临界流体萃取步骤，每个馏分使用不同的溶剂化条件。 因此，实现生物质的分馏，并且制造圣约翰草产品。 除了优异的总产量外，具有超临界和近临界流体的具有和不具有极性助溶剂的金丝桃生物质生产的圣约翰草产品的生物活性和稳定性显着高于通过常规有机相萃取获得的生物活性和稳定性。

    CONTINUOUS FLOW, HIGH THROUGHPUT APPARATUS AND METHOD FOR INACTIVATING VIRUSES AND PATHOGENS IN HUMAN PLASMA
    6.
    发明公开
    CONTINUOUS FLOW, HIGH THROUGHPUT APPARATUS AND METHOD FOR INACTIVATING VIRUSES AND PATHOGENS IN HUMAN PLASMA 审中-公开

    公开(公告)号：US20240350691A1

    公开(公告)日：2024-10-24

    申请号：US18031574

    申请日：2021-10-12

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: A61L2/24 ,  A61L2/00

    CPC classification number: A61L2/24 ,  A61L2/0011 ,  A61L2202/14 ,  A61L2202/15 ,  A61L2202/16 ,  A61L2202/22

    Abstract: The present invention is for a continuous-flow pathogen reduction apparatus and method, based purely on pathogen inactivation physical principles, for controlling or eliminating trans fusion-transmittable infections from emerging pathogens, pandemic viruses, and bioterrorism threats. The invention inactivates both nonenveloped and enveloped viruses as well as pathogenic bacteria and parasites in human plasma and biologies, while retaining the natural bioactivity, integrity and potency of the treated biologic. The method uses critic al, near-critical or supercritical fluids for viral and pathogen reduction of plasma and biologies. The apparatus is designed to rapidly process high volumes of plasma and biologies with high levels of pathogen reduction in a continuous flow fashion.

    ENHANCED GINGEROLS FOR PATIENTS SUFFERING FROM NAUSEA AND EMESIS
    8.
    发明公开
    ENHANCED GINGEROLS FOR PATIENTS SUFFERING FROM NAUSEA AND EMESIS 审中-公开

    公开(公告)号：US20230414697A1

    公开(公告)日：2023-12-28

    申请号：US18037069

    申请日：2021-11-15

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: A61K36/9068 ,  A61K31/12 ,  A61K9/48

    CPC classification number: A61K36/9068 ,  A61K31/12 ,  A61K9/4858 ,  A61K9/4875 ,  A61K2236/37

    Abstract: This invention relates to a composition of matter using enhanced gingerols for treating nausea and emesis associated with cancer chemotherapy, pregnancy, elective surgery, radiation therapy, motion sickness, and drug medications, use and schedule of use as well as methods of making. A method of making the enhanced gingerols features supercritical, critical and near-critical fluids with and without polar cosolvents. The capsules include an enhanced extract of ginger rhizome wherein said ginger rhizome has a starting mass and said extract has a 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol mass and said ratio of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol mass to starting mass is 90-100%.

    MAGNETIC NANOPARTICLE PLAQUE CLEARANCE
    10.
    发明申请
    MAGNETIC NANOPARTICLE PLAQUE CLEARANCE 有权

    公开(公告)号：US20220203113A1

    公开(公告)日：2022-06-30

    申请号：US17561799

    申请日：2021-12-24

    Applicant: Trevor Percival Castor

    Inventor： Trevor Percival Castor

    IPC: A61N2/00 ,  A61N2/02

    Abstract: This invention relates to methods and systems for removing plaque from arteries and blood vessels in human subjects non-invasively utilizing coated superparamagnetic nanoparticles introduced into the human bloodstream and controlled by external magnetic fields to effect plaque removal. Magnetic nanoparticles are injected into a patient, and magnetic fields are used to move the nanoparticles to the site of an arterial blockage. The nanoparticles are then oscillated by means of an alternating current source and oscillating magnetic field. The nanoparticles impact the plaque deposit, causing it to break up, so that it may be safely disintegrated, dissolved in the bloodstream, digested by enzymes or ions and/or removed with the nanoparticles themselves. The nanoparticles are removed by a unipolar magnetic field directing them to be removed at the point of injection or alternative location in the body. The nanoparticles are also removed by natural bodily functions. The methods and systems are directed to the emergency clearance of arteries in the human body, and the routine annual and quarterly clearance and preventative maintenance of arteries in the human body.

Patent Agency Ranking